Using platelet-specific as well as global P2Y12-deficiency models and treatment with the potent P2Y12 inhibitor prasugrel, we demonstrate that P2Y12 inhibition reduces emergency hematopoiesis and the excessive inflammatory response to MI, subsequently preserving cardiac function and preventing adverse cardiac remodeling after MI. The gene discussed is P2RY12; the disease is myocardial infarction.